Aarti Drugs soars after share buyback proposal | Capital Market News

Shares of Aarti Drugs rose 6.86% to Rs 570.45 after the company announced that its board will meet on Monday, August 26, 2024, to consider a proposal to buy back the company’s fully paid ordinary shares.

This information was announced yesterday after the end of the trading session.

Aarti Drugs is a part of the $6 billion Aarti Group of Industries with a robust R&D facility at Tarapur, Maharashtra Industrial Development Corporation (MIDC) near its manufacturing facilities. The company is engaged in the production of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Intermediates, Specialty Chemicals and manufactures formulations with its wholly owned subsidiary – Pinnacle Life Science Private.

Disclaimer: No Business Standard journalist was involved in the creation of this content